Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The **D-alanyl-D-alanine terminus in peptidoglycan precursor** is a chemical motif representing the C-terminal end of the peptide stem in the peptidoglycan precursors of most bacterial cell walls. This dipeptide, added by the enzyme D-alanine-D-alanine ligase, is crucial for the proper cross-linking of peptidoglycan layers in both Gram-positive and Gram-negative bacteria, providing rigidity and maintaining cell shape. During cell wall synthesis, the D-Ala-D-Ala end serves as the specific binding site for glycopeptide antibiotics such as vancomycin, which form a stable complex with this motif and block further extension and cross-linking of the cell wall—ultimately causing bacterial death[1][2][3][4][5][6][7]. The D-Ala-D-Ala motif is also mimicked by β-lactam antibiotics to competitively inhibit cell wall transpeptidation. Bacterial resistance, notably vancomycin resistance, can arise by altering this terminus (e.g., replacing D-Ala-D-Ala with D-Ala-D-Lac), greatly reducing antibiotic binding affinity and efficacy[1]. This structure is unique to bacteria and absent in mammalian cells, making it an excellent, selective antibacterial drug target.
Glycopeptide antibiotics (e.g., vancomycin) bind the D-Ala-D-Ala terminus, blocking peptidoglycan cross-linking and thus inhibiting bacterial cell wall synthesis, leading to cell death[1]. β-lactam antibiotics mimic the D-Ala-D-Ala structure, competitively inhibiting transpeptidases (penicillin-binding proteins), and preventing peptidoglycan cross-linking[5].
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on D-alanyl-D-alanine terminus in peptidoglycan precursor (D-Ala-D-Ala terminus).